Screener / SEC EDGAR /CIK 0001521036 /10-K filed Feb 26, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Diagnostics

Lantheus Holdings, Inc. LNTH

Compare with peers Embed
Earnings releases

Latest results release: Nov 5, 2026

8-K item 2.02, exhibit 99

What LNTH's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 5, 2026 · EX-99.1

Lantheus Reports Third Quarter 2026 Financial Results • Worldwide revenue of

Open on SEC

Exhibit 99.1 Lantheus Reports Third Quarter 2026 Financial Results • Worldwide revenue of $389.9 million in the third quarter of 2026 • GAAP fully diluted earnings per share of $0.33, compared to $0.41 in the third quarter of 2025 • Adjusted fully diluted earnings per share of $1.68, compared to $1.27 in the third quarter of 2025 • FDA approves TAUKLARIFY ™ (florquinitau F-18 injection); an F-18-labeled tau PET imaging agent for the evaluation of adults with cognitive impairment being assessed for Alzheimer’s disease • FDA grants final approval for BRAVNETSA ™ (lutetium Lu 177 dotatate); the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to LUTATHERA ® for the treatment of adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) • Announced on August 3, 2026 that the Company has entered into a definitive agreement to merge with Curium under which Curium US Holdings LLC will acquire all outstanding shares of the Company in an all-cash transaction that represents a total transaction value of up to approximately $8.0 billion BEDFORD, Mass., November 5, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today reported financial results for its third quarter ended September 30, 2026. In addition, and as previously announced, Lantheus entered into a definitive agreement on August 3, 2026 to merge with Curium under which Curium US Holdings LLC will acquire all outstanding shares of Lantheus for $102.50 per share in cash at closing, plus non-transferable Contingent Value Rights (“CVRs”) providing for up to $12.00 per share in potential additional cash payments, subject to achievement of specified commercial milestones for Lantheus’ products through 2030. The transaction represents a total per share consideration of up to $114.50 and a total transaction value of up to approximately $8.0 billion. Together, Curium and Lantheus are positioned to create a radiopharmaceutical company spanning diagnostics and therapeutics, with the infrastructure and capabilities to serve patients in more than 70 countries. The Board of Directors of Lantheus has unanimously approved the transaction. Additional information regarding the transaction is available in the Company’s Current Report on Form 8-K filed with the SEC on August 4, 2026. In connection with the pending transaction, Lantheus is suspending its previously issued full year 2026 financial guidance and will not be hosting a conference call in connection with its third quarter 2026 results. Summary Financial Results

Third Quarter 2026 • Worldwide revenue increased 1.5% to $389.9 million compared to the same period in 2025. • Sales of PYLARIFY were $238.9 million, a decrease of 0.7%. Page1of 11 Sales of Neuraceq were $45.6 million, an increase of 123.0%.

Operating income decreased 26.2% to $32.2 million. Adjusted operating income (non-GAAP) increased 28.1% to $153.2 million.

Fully diluted earnings per share decreased 19.5% to $0.33, compared to fully diluted earnings per share of $0.41 in the prior year period. Adjusted fully diluted earnings per share (non-GAAP) increased 32.3% to $1.68, compared to $1.27 in the prior year period.

Net cash provided by operating activities and free cash flow were $102.0 million and $99.9 million, respectively.

At September 30, 2026, the Company's cash and cash equivalents were $683.6 million, compared to $359.1 million at December 31, 2025.

The Company currently has access to up to $750.0 million from a revolving line of credit.

Received CMS Transitional Pass-Through payment status and a permanent HCPCS code, each effective October 1, 2026, for PYLARIFY ® TruVu ™ (piflufolastat F18), supporting the Company’s previously announced phased geographic commercial launch.

Received FDA approval for TAUKLARIFY (florquinitau F-18 injection), an F-18-labeled tau PET imaging agent for the evaluation of adults with cognitive impairment being assessed for Alzheimer’s disease. The Company intends to continue supporting Alzheimer’s disease therapeutic programs through its Pharma Solutions business while assessing the appropriate path toward broader commercial availability.

Received final FDA approval for BRAVNETSA (lutetium Lu 177 dotatate), the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to LUTATHERA ® for the treatment of adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors; the Company is preparing for a thoughtful commercial launch to support reliable supply and broad patient access.

Dosed the first patient in the SPARROW study, a Phase 2/3 registrational trial evaluating LNTH-2401, the Company’s investigational GRPR-targeted PET imaging agent for prostate cancer; the Phase 3 portion is expected to enroll approximately 400 participants and evaluate diagnostic performance, safety and tolerability.

Lantheus is the leading radiopharmaceutical-focused company, delivering life- changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Switzerland, Sweden and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years. For more information, visit www.lantheus.com.

The Company routinely posts information that may be important to investors in the “Investors” section of its website at www.lantheus.com. The Company encourages investors and potential investors to consult its website regularly for important information about the Company.

The Company uses non-GAAP financial measures, such as adjusted net income and its line components; adjusted fully diluted net income per share; adjusted operating income, and free cash flow. The Company’s management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company’s operations, period over period. However, these measures may exclude items that may be highly variable, difficult to predict and of a size that could have a substantial impact on the Company’s reported results of operations for a particular period. Management uses these and other non-GAAP measures internally for evaluation of the performance of the business, including the evaluation of results relative to employee performance compensation targets. Investors should consider these non- GAAP measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP. Page2of 11 Safe Harbor for Forward-Looking and Cautionary Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by their use of terms such as “advance,” “believe,” “continue,” “could,” “driving,” “expect,” “guidance,” “maintain,” “may,” “on track,” “plan,” “potential,” “predict,” “progress,” “should,” “target,” “will,” “would” and other similar terms, or by express or implied discussions regarding the pending merger with Curium (the “Merger”). Such forward-looking statements include our plans to successfully execute on the commercialization of marketed products, ensure launch readiness for new products, advance a focused late-stage pipeline, and allocate capital thoughtfully, and our focus mainly on our radiodiagnostic business and pursuing value-maximizing alternatives for our radiotherapeutic assets, and are based upon current plans, estimates and expectations that are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Readers are cautioned not to place undue reliance on the forward- looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements include: (i) continued market expansion, penetration and reimbursement for our established commercial products, particularly PYLARIFY, DEFINITY and Neuraceq, in a competitive environment and our ability to clinically and commercially differentiate our products; (ii) our ability to complete the technology transfer across our positron emission tomography (“PET”) manufacturing facilities (“PMF”) network for PYLARIFY TruVu, the new formulation of our F-18 prostate-specific membrane antigen (“PSMA”) PET imaging agent approved by the U.S. Food and Drug Administration (“FDA”) on March 6, 2026, to obtain FDA approval for each PMF to manufacture PYLARIFY TruVu, to maintain adequate coverage and payment for PYLARIFY TruVu, including the transitional pass-through payment status (“TPT Status”) granted by the Centers for Medicare & Medicaid Services, as announced on September 30, 2026, to have payers add Healthcare Common Procedure Coding System (“HCPCS”) code for PYLARIFY TruVu effective October 1, 2026 to their systems on a timely basis and to have customers adopt PYLARIFY TruVu; (iii) the availability of raw materials, key components, equipment, manufacturing time slots, either used in the production of our products and product candidates, or by customers of our products and product candidates, including, but not limited to PET scanners for PYLARIFY, PYLARIFY TruVu, Neuraceq, TAUKLARIFY, LNTH-2501 and NAV-4694; (iv) our ability to have third parties manufacture our products and product candidates and our ability to manufacture DEFINITY in our in-house manufacturing facility, in amounts and at the times needed; (v) our ability to satisfy our obligations under our existing clinical development partnerships using Neuraceq, MK-6240 or NAV-4694 and other assets as a research tool and under the license agreements through which we have rights to those assets, to support TAUKLARIFY (florquinitau F-18 injection), also referred to as MK-6240, which was approved by the FDA on August 14, 2026, including through our Pharma Solutions business, and to determine an appropriate path and timing toward its broader commercial availability, and to further develop and commercialize NAV-4694 as an approved product; (vi) our ability to continue to successfully integrate acquisitions, including of Lantheus Biosciences, which could be impacted by unforeseen expenses related to integration activities, the potential for unforeseen liabilities within that business, the ability to integrate disparate information technology systems, retain key talent and create a merged corporate culture that successfully realizes the full potential of the combined organization; (vii) our ability to obtain FDA approval for LNTH-2501, our investigational kit for the preparation of Gallium-68 edotreotide injection, which has been studied for use in conjunction with a PET scan to stage and localize neuroendocrine tumors in adult and pediatric patients, including satisfactorily resolving certain unresolved third-party facility inspection-related conditions identified in the Complete Response Letter issued by the FDA on June 26, 2026 and obtaining approval of a resubmitted new drug application, and to successfully commercialize LNTH-2501, if approved; (viii) the timing, execution and success of our planned commercialization of BRAVNETSA (lutetium Lu 177 dotatate), previously known as PNT2003, which received final FDA approval on September 22, 2026, including in light of competing lutetium Lu 177 dotatate products, our ability to successfully defend the favorable U.S. District Court ruling invalidating all patents asserted in the related Hatch-Waxman litigation, which is currently on appeal before the U.S. Court of Appeals for the Federal Circuit, and our dependence on POINT Biopharma Global Inc. to manufacture and supply BRAVNETSA; (ix) the cost, efforts and timing for clinical development, manufacturing, regulatory approval, adequate coding, coverage and payment and successful commercialization of our newly approved products, product candidates and new clinical applications and territories for our products, in each case, that we or our strategic partners may undertake, including the SPARROW Phase 2/3 registrational trial of LNTH-2401, and the risk of further impairment of our in- process research and development assets; (x) the timing, execution, and success of our strategic program to simplify and streamline our operations so we can focus mainly on our radiodiagnostic business and pursue value-maximizing alternatives for our radiotherapeutic assets; (xi) our ability to identify opportunities to collaborate with strategic partners and to acquire or in- license additional product opportunities in oncology, neurology and other strategic areas and continue to grow and advance our pipeline of products, subject to the restrictions on the conduct of our business under the Agreement and Plan of Merger, dated as of August 3, 2026 (the “Merger Agreement”), by and among us, Curium US Holdings LLC (the “Parent”), and Coco Merger Sub Inc.; (xii) the timing and outcome of the actions filed against us by alleged stockholders, and of demands or litigation relating to the transactions contemplated by the Merger Agreement; (xiii) the effect that changes to management could have on our business; (xiv) our ability and the ability of the Parent to Page3of 11 complete the transactions contemplated by the Merger Agreement, including the parties’ ability to satisfy the remaining closing conditions in the agreement, including the expiration or termination of the waiting period under the Hart- Scott-Rodino Antitrust Improvements Act of 1976, as amended (which was extended on October 21, 2026 by the Federal Trade Commission), and the receipt of other required antitrust and foreign direct investment approvals; (xv) statements about the expected time frame for completing the proposed Merger; (xvi) our and the Parent’s beliefs and expectations and statements about the benefits sought to be achieved by the proposed Merger; (xvii) the potential effects of the proposed Merger on us and the Parent, including on our relationships with customers, suppliers and employees, and the costs we have incurred and will incur in connection with the proposed Merger whether or not it is completed; (xviii) the possibility of any termination of the Merger Agreement, including in circumstances that would require us to pay a termination fee; (xix) whether any payments will be made under the contingent value rights to be issued in the proposed Merger; and (xx) the risks and uncertainties discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q). - Tables Follow -

Page4of 11 Lantheus Holdings, Inc. Consolidated Statements of Operations (in thousands, except per share data – unaudited)

Page5of 11 Lantheus Holdings, Inc. Consolidated Revenues Analysis (in thousands, except percent data – unaudited)

Page6of 11 Lantheus Holdings, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures (in thousands, except per share and percent data – unaudited)

(a) Represents the estimated income tax effect of the adjustments between GAAP net income and adjusted net income (non-GAAP). (b) Amounts may not add due to rounding. Page7of 11 Lantheus Holdings, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures (Continued) (in thousands, except per share and percent data – unaudited)

Page8of 11 Lantheus Holdings, Inc. Reconciliation of Free Cash Flow (in thousands – unaudited)

Page9of 11 Lantheus Holdings, Inc. Condensed Consolidated Balance Sheets (in thousands – unaudited)

Assets September 30, December 31, Current assets: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Cash and cash $ 683,610 $ 359,121 equivalents Accounts receivable, 345,684 358,640 net Inventory, net 64,212 64,674 Income tax receivable — 15,387 Other current assets 30,204 21,400 Assets held for sale — 80,742 Total current assets 1,123,710 899,964 Investment in equity 98,427 42,213 securities Long-term notes 25,297 — receivable Property, plant and 149,627 163,686 equipment, net Intangibles, net 641,612 722,779 Goodwill 238,626 239,517 Deferred tax assets, 121,135 109,196 net Other long-term 57,699 50,044 assets Total assets $ 2,456,133 $ 2,227,399 Liabilities and Stockholders’ Equity Current liabilities: Current portion of long-term debt and $ 605 $ 738 other borrowings Accounts payable 47,700 42,906 Accrued expenses and other current 297,662 267,307 liabilities Liabilities held for — 22,468 sale Total current 345,967 333,419 liabilities Asset retirement 257 138 obligations Long-term debt and other borrowings, net 571,136 568,678 of current portion Long-term deferred 41,136 54,246 tax liabilities Long-term contingent consideration 51,657 73,255 liabilities, net of current portion Other long-term 90,268 107,866 liabilities Total liabilities 1,100,421 1,137,602 Total stockholders’ 1,355,712 1,089,797 equity Total liabilities and stockholders’ $ 2,456,133 $ 2,227,399 equity

Full text with the tables
Exhibit 99.1
Lantheus Reports Third Quarter 2026 Financial Results • Worldwide revenue of
$389.9 million in the third quarter of 2026 • GAAP fully diluted earnings per
share of $0.33, compared to $0.41 in the third quarter of 2025 • Adjusted fully
diluted earnings per share of $1.68, compared to $1.27 in the third quarter of
2025 • FDA approves TAUKLARIFY ™ (florquinitau F-18 injection); an F-18-labeled
tau PET imaging agent for the evaluation of adults with cognitive impairment
being assessed for Alzheimer’s disease • FDA grants final approval for BRAVNETSA
™ (lutetium Lu 177 dotatate); the only radiopharmaceutical the FDA has
determined to be bioequivalent and therapeutically equivalent to LUTATHERA ® for
the treatment of adults with somatostatin receptor-positive
gastroenteropancreatic neuroendocrine tumors (GEP-NETs) • Announced on August 3,
2026 that the Company has entered into a definitive agreement to merge with
Curium under which Curium US Holdings LLC will acquire all outstanding shares of
the Company in an all-cash transaction that represents a total transaction value
of up to approximately $8.0 billion BEDFORD, Mass., November 5, 2026 (GLOBE
NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH),
the leading radiopharmaceutical-focused company committed to enabling clinicians
to Find, Fight and Follow disease to deliver better patient outcomes, today
reported financial results for its third quarter ended September 30, 2026. In
addition, and as previously announced, Lantheus entered into a definitive
agreement on August 3, 2026 to merge with Curium under which Curium US Holdings
LLC will acquire all outstanding shares of Lantheus for $102.50 per share in
cash at closing, plus non-transferable Contingent Value Rights (“CVRs”)
providing for up to $12.00 per share in potential additional cash payments,
subject to achievement of specified commercial milestones for Lantheus’ products
through 2030. The transaction represents a total per share consideration of up
to $114.50 and a total transaction value of up to approximately $8.0 billion.
Together, Curium and Lantheus are positioned to create a radiopharmaceutical
company spanning diagnostics and therapeutics, with the infrastructure and
capabilities to serve patients in more than 70 countries. The Board of Directors
of Lantheus has unanimously approved the transaction. Additional information
regarding the transaction is available in the Company’s Current Report on Form
8-K filed with the SEC on August 4, 2026. In connection with the pending
transaction, Lantheus is suspending its previously issued full year 2026
financial guidance and will not be hosting a conference call in connection with
its third quarter 2026 results. Summary Financial Results
                                                                                
               (in                                                              
               millions,     Three Months                                       
               except per    Ended                                              
               share data    September                                          
               - unaudited)  30,            2026        2025      % Change      
 ────────────────────────────────────────────────────────────────────────────── 
  Worldwide                  $             389.9    $  384.0           1.5  %   
  revenue                                                                       
  GAAP net                   $              22.4    $   27.8         (19.4  %)  
  income                                                                        
  GAAP fully                                                                    
  diluted                    $              0.33    $   0.41         (19.5  %)  
  earnings                                                                      
  per share                                                                     
  Adjusted                                                                      
  net income                 $             115.1    $   85.7          34.3  %   
  (non-GAAP)                                                                    
  Adjusted                                                                      
  fully                                                                         
  diluted                                                                       
  earnings                   $              1.68    $   1.27          32.3  %   
  per                                                                           
  share                                                                         
  (non-GAAP)                                                                    
                                                                                
Third Quarter 2026 • Worldwide revenue increased 1.5% to $389.9 million compared
to the same period in 2025. • Sales of PYLARIFY were $238.9 million, a decrease
of 0.7%.
                                   Page1of 11                                   
Sales of Neuraceq were $45.6 million, an increase of 123.0%.                    
                                                                                
Sales of DEFINITY were $85.7 million, an increase of 4.8%.                      
                                                                                
Operating income decreased 26.2% to $32.2 million. Adjusted operating income    
(non-GAAP) increased 28.1% to $153.2 million.                                   
                                                                                
Fully diluted earnings per share decreased 19.5% to $0.33, compared to fully    
diluted earnings per share of $0.41 in the prior year period. Adjusted fully    
diluted earnings per share (non-GAAP) increased 32.3% to $1.68, compared to     
$1.27 in the prior year period.                                                 
                                                                                
Net cash provided by operating activities and free cash flow were $102.0 million
and $99.9 million, respectively.                                                
                                                                                
Balance Sheet                                                                   
                                                                                
At September 30, 2026, the Company's cash and cash equivalents were $683.6      
million, compared to $359.1 million at December 31, 2025.                       
                                                                                
The Company currently has access to up to $750.0 million from a revolving line  
of credit.                                                                      
                                                                                
Recent Business Highlights                                                      
                                                                                
Received CMS Transitional Pass-Through payment status and a permanent HCPCS     
code, each effective October 1, 2026, for PYLARIFY ® TruVu ™ (piflufolastat     
F18), supporting the Company’s previously announced phased geographic commercial
launch.                                                                         
                                                                                
Received FDA approval for TAUKLARIFY (florquinitau F-18 injection), an          
F-18-labeled tau PET imaging agent for the evaluation of adults with cognitive  
impairment being assessed for Alzheimer’s disease. The Company intends to       
continue supporting Alzheimer’s disease therapeutic programs through its Pharma 
Solutions business while assessing the appropriate path toward broader          
commercial availability.                                                        
                                                                                
Received final FDA approval for BRAVNETSA (lutetium Lu 177 dotatate), the only  
radiopharmaceutical the FDA has determined to be bioequivalent and              
therapeutically equivalent to LUTATHERA ® for the treatment of adults with      
somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors; the
Company is preparing for a thoughtful commercial launch to support reliable     
supply and broad patient access.                                                
                                                                                
Dosed the first patient in the SPARROW study, a Phase 2/3 registrational trial  
evaluating LNTH-2401, the Company’s investigational GRPR-targeted PET imaging   
agent for prostate cancer; the Phase 3 portion is expected to enroll            
approximately 400 participants and evaluate diagnostic performance, safety and  
tolerability.                                                                   
                                                                                
About Lantheus                                                                  
                                                                                
Lantheus is the leading radiopharmaceutical-focused company, delivering life-   
changing science to enable clinicians to Find, Fight and Follow disease to      
deliver better patient outcomes. Headquartered in Massachusetts with offices in 
New Jersey, Canada, Germany, Switzerland, Sweden and the United Kingdom,        
Lantheus has been providing radiopharmaceutical solutions for 70 years. For more
information, visit www.lantheus.com.                                            
                                                                                
Internet Posting of Information                                                 
                                                                                
The Company routinely posts information that may be important to investors in   
the “Investors” section of its website at www.lantheus.com. The Company         
encourages investors and potential investors to consult its website regularly   
for important information about the Company.                                    
                                                                                
Non-GAAP Financial Measures                                                     
                                                                                
The Company uses non-GAAP financial measures, such as adjusted net income and   
its line components; adjusted fully diluted net income per share; adjusted      
operating income, and free cash flow. The Company’s management believes that the
presentation of these measures provides useful information to investors. These  
measures may assist investors in evaluating the Company’s operations, period    
over period. However, these measures may exclude items that may be highly       
variable, difficult to predict and of a size that could have a substantial      
impact on the Company’s reported results of operations for a particular period. 
Management uses these and other non-GAAP measures internally for evaluation of  
the performance of the business, including the evaluation of results relative to
employee performance compensation targets. Investors should consider these non- 
GAAP measures only as a supplement to, not as a substitute for or as superior   
to, measures of financial performance prepared in accordance with GAAP.         
                                   Page2of 11                                   
Safe Harbor for Forward-Looking and Cautionary Statements                       
                                                                                
This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, as amended, that are subject  
to risks and uncertainties and are made pursuant to the safe harbor provisions  
of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking statements   
may be identified by their use of terms such as “advance,” “believe,”           
“continue,” “could,” “driving,” “expect,” “guidance,” “maintain,” “may,” “on    
track,” “plan,” “potential,” “predict,” “progress,” “should,” “target,” “will,” 
“would” and other similar terms, or by express or implied discussions regarding 
the pending merger with Curium (the “Merger”). Such forward-looking statements  
include our plans to successfully execute on the commercialization of marketed  
products, ensure launch readiness for new products, advance a focused late-stage
pipeline, and allocate capital thoughtfully, and our focus mainly on our        
radiodiagnostic business and pursuing value-maximizing alternatives for our     
radiotherapeutic assets, and are based upon current plans, estimates and        
expectations that are subject to risks and uncertainties that could cause actual
results to materially differ from those described in the forward-looking        
statements. The inclusion of forward-looking statements should not be regarded  
as a representation that such plans, estimates and expectations will be         
achieved. Readers are cautioned not to place undue reliance on the forward-     
looking statements contained herein, which speak only as of the date hereof. The
Company undertakes no obligation to publicly update any forward-looking         
statement, whether as a result of new information, future developments or       
otherwise, except as may be required by law. Risks and uncertainties that could 
cause our actual results to materially differ from those described in the       
forward-looking statements include: (i) continued market expansion, penetration 
and reimbursement for our established commercial products, particularly         
PYLARIFY, DEFINITY and Neuraceq, in a competitive environment and our ability to
clinically and commercially differentiate our products; (ii) our ability to     
complete the technology transfer across our positron emission tomography (“PET”)
manufacturing facilities (“PMF”) network for PYLARIFY TruVu, the new formulation
of our F-18 prostate-specific membrane antigen (“PSMA”) PET imaging agent       
approved by the U.S. Food and Drug Administration (“FDA”) on March 6, 2026, to  
obtain FDA approval for each PMF to manufacture PYLARIFY TruVu, to maintain     
adequate coverage and payment for PYLARIFY TruVu, including the transitional    
pass-through payment status (“TPT Status”) granted by the Centers for Medicare &
Medicaid Services, as announced on September 30, 2026, to have payers add       
Healthcare Common Procedure Coding System (“HCPCS”) code for PYLARIFY TruVu     
effective October 1, 2026 to their systems on a timely basis and to have        
customers adopt PYLARIFY TruVu; (iii) the availability of raw materials, key    
components, equipment, manufacturing time slots, either used in the production  
of our products and product candidates, or by customers of our products and     
product candidates, including, but not limited to PET scanners for PYLARIFY,    
PYLARIFY TruVu, Neuraceq, TAUKLARIFY, LNTH-2501 and NAV-4694; (iv) our ability  
to have third parties manufacture our products and product candidates and our   
ability to manufacture DEFINITY in our in-house manufacturing facility, in      
amounts and at the times needed; (v) our ability to satisfy our obligations     
under our existing clinical development partnerships using Neuraceq, MK-6240 or 
NAV-4694 and other assets as a research tool and under the license agreements   
through which we have rights to those assets, to support TAUKLARIFY             
(florquinitau F-18 injection), also referred to as MK-6240, which was approved  
by the FDA on August 14, 2026, including through our Pharma Solutions business, 
and to determine an appropriate path and timing toward its broader commercial   
availability, and to further develop and commercialize NAV-4694 as an approved  
product; (vi) our ability to continue to successfully integrate acquisitions,   
including of Lantheus Biosciences, which could be impacted by unforeseen        
expenses related to integration activities, the potential for unforeseen        
liabilities within that business, the ability to integrate disparate information
technology systems, retain key talent and create a merged corporate culture that
successfully realizes the full potential of the combined organization; (vii) our
ability to obtain FDA approval for LNTH-2501, our investigational kit for the   
preparation of Gallium-68 edotreotide injection, which has been studied for use 
in conjunction with a PET scan to stage and localize neuroendocrine tumors in   
adult and pediatric patients, including satisfactorily resolving certain        
unresolved third-party facility inspection-related conditions identified in the 
Complete Response Letter issued by the FDA on June 26, 2026 and obtaining       
approval of a resubmitted new drug application, and to successfully             
commercialize LNTH-2501, if approved; (viii) the timing, execution and success  
of our planned commercialization of BRAVNETSA (lutetium Lu 177 dotatate),       
previously known as PNT2003, which received final FDA approval on September 22, 
2026, including in light of competing lutetium Lu 177 dotatate products, our    
ability to successfully defend the favorable U.S. District Court ruling         
invalidating all patents asserted in the related Hatch-Waxman litigation, which 
is currently on appeal before the U.S. Court of Appeals for the Federal Circuit,
and our dependence on POINT Biopharma Global Inc. to manufacture and supply     
BRAVNETSA; (ix) the cost, efforts and timing for clinical development,          
manufacturing, regulatory approval, adequate coding, coverage and payment and   
successful commercialization of our newly approved products, product candidates 
and new clinical applications and territories for our products, in each case,   
that we or our strategic partners may undertake, including the SPARROW Phase 2/3
registrational trial of LNTH-2401, and the risk of further impairment of our in-
process research and development assets; (x) the timing, execution, and success 
of our strategic program to simplify and streamline our operations so we can    
focus mainly on our radiodiagnostic business and pursue value-maximizing        
alternatives for our radiotherapeutic assets; (xi) our ability to identify      
opportunities to collaborate with strategic partners and to acquire or in-      
license additional product opportunities in oncology, neurology and other       
strategic areas and continue to grow and advance our pipeline of products,      
subject to the restrictions on the conduct of our business under the Agreement  
and Plan of Merger, dated as of August 3, 2026 (the “Merger Agreement”), by and 
among us, Curium US Holdings LLC (the “Parent”), and Coco Merger Sub Inc.; (xii)
the timing and outcome of the actions filed against us by alleged stockholders, 
and of demands or litigation relating to the transactions contemplated by the   
Merger Agreement; (xiii) the effect that changes to management could have on our
business; (xiv) our ability and the ability of the Parent to                    
                                   Page3of 11                                   
complete the transactions contemplated by the Merger Agreement, including the   
parties’ ability to satisfy the remaining closing conditions in the agreement,  
including the expiration or termination of the waiting period under the Hart-   
Scott-Rodino Antitrust Improvements Act of 1976, as amended (which was extended 
on October 21, 2026 by the Federal Trade Commission), and the receipt of other  
required antitrust and foreign direct investment approvals; (xv) statements     
about the expected time frame for completing the proposed Merger; (xvi) our and 
the Parent’s beliefs and expectations and statements about the benefits sought  
to be achieved by the proposed Merger; (xvii) the potential effects of the      
proposed Merger on us and the Parent, including on our relationships with       
customers, suppliers and employees, and the costs we have incurred and will     
incur in connection with the proposed Merger whether or not it is completed;    
(xviii) the possibility of any termination of the Merger Agreement, including in
circumstances that would require us to pay a termination fee; (xix) whether any 
payments will be made under the contingent value rights to be issued in the     
proposed Merger; and (xx) the risks and uncertainties discussed in our filings  
with the Securities and Exchange Commission (including those described in the   
Risk Factors section in our Annual Reports on Form 10-K and our Quarterly       
Reports on Form 10-Q).                                                          
                               - Tables Follow -                                
                                                                                
                                   Page4of 11                                   
Lantheus Holdings, Inc. Consolidated Statements of Operations (in thousands,
except per share data – unaudited)
                                                                                
                Three                                Nine                       
                Mont…                               Mont…                       
                Ended                               Ended                       
                Sept…                               Sept…                       
          2026    30,       2025              2026    30,       2025            
 ────────────────────────────────────────────────────────────────────────────── 
  Rev…    $     389,…       $     384,…       $     1,15…       $     1,13…     
  Cost                                                                          
  of            146,…             161,…             439,…             433,…     
  goo…                                                                          
  sold                                                                          
  Gro…          243,…             222,…             716,…             701,…     
  pro…                                                                          
  Ope…                                                                          
  exp…                                                                          
  Sal…                                                                          
  and           48,0…             48,8…             183,…             132,…     
  mar…                                                                          
  Gen…                                                                          
  and           70,3…             81,8…             148,…             205,…     
  adm…                                                                          
  Res…                                                                          
  and           92,7…             48,0…             170,…             129,…     
  dev…                                                                          
  Tot…                                                                          
  ope…          211,…             178,…             502,…             467,…     
  exp…                                                                          
  Ope…          32,2…             43,6…             213,…             233,…     
  inc…                                                                          
  Int…          4,940             4,950             14,7…             14,6…     
  exp…                                                                          
  Net                                                                           
  loss                                                                          
  (ga…                                                                          
  on            12,1…             (1,1…  )          6,795              (871  )  
  inv…                                                                          
  in                                                                            
  equ…                                                                          
  sec…                                                                          
  Loss                                                                          
  (ga…                                                                          
  on                                                                            
  sale                                                                          
  of               83                 —             (59,…  )              —     
  bus…                                                                          
  net                                                                           
  of                                                                            
  tra…                                                                          
  cos…                                                                          
  Oth…                                                                          
  inc…          (6,7…  )          (2,5…  )          (20,…  )          (23,…  )  
  net                                                                           
  Inc…                                                                          
  bef…          21,7…             42,3…             272,…             243,…     
  inc…                                                                          
  tax…                                                                          
  Inc…                                                                          
  tax            (594  )          14,6…             56,1…             63,9…     
  (be…                                                                          
  exp…                                                                          
  Net     $     22,3…       $     27,7…       $     215,…       $     179,…     
  inc…                                                                          
  Net                                                                           
  inc…                                                                          
  per                                                                           
  com…                                                                          
  sha…                                                                          
  Bas…    $      0.34       $      0.41       $      3.32       $      2.63     
  Dil…    $      0.33       $      0.41       $      3.21       $      2.60     
  Wei…                                                                          
  ave…                                                                          
  com…                                                                          
  sha…                                                                          
  out…                                                                          
  Bas…          65,2…             67,2…             65,0…             68,1…     
  Dil…          68,4…             67,6…             67,1…             69,0…     
                                                                                
                                   Page5of 11                                   
Lantheus Holdings, Inc. Consolidated Revenues Analysis (in thousands, except
percent data – unaudited)
                                                                                
       …                                      …                                 
       …                                      …                                 
    …  …               …          …        …  …               …                 
    …  …       …       $          %        …  …       …       $                 
 ────────────────────────────────────────────────────────────────────────────── 
       $  …    $  …    $  …  )       …  …     $  …    $  …    $  …  )      …    
          …       …       …  )       …  …        …       …       …  )      …    
          …       …       …          …  %        …       …       …         …    
          …       …       …          …  %        …       …       …         …    
          …       …       …          …  %        …       …       …         …    
          …       …       …          …  %        …       …       …         …    
          …       …       …          …  %        …       …       …         …    
          —       …       …  )       …  …        —       …       …  )      …    
       $  …    $  …    $  …          …  %     $  …    $  …    $  …         …    
                                                                                
                                   Page6of 11                                   
Lantheus Holdings, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures
(in thousands, except per share and percent data – unaudited)
                                                                                
                Three                                Nine                       
                Mont…                               Mont…                       
                Ended                               Ended                       
                Sept…                               Sept…                       
          2026    30,       2025              2026    30,       2025            
 ────────────────────────────────────────────────────────────────────────────── 
  Net     $     22,3…       $     27,7…       $     215,…       $     179,…     
  inc…                                                                          
  Sto…                                                                          
  and                                                                           
  inc…          21,8…             24,5…             57,9…             68,0…     
  plan                                                                          
  com…                                                                          
  Amo…                                                                          
  of                                                                            
  acq…          16,7…             14,6…             50,1…             30,6…     
  int…                                                                          
  ass…                                                                          
  Imp…                                                                          
  of            31,0…                 —             31,0…                 —     
  int…                                                                          
  ass…                                                                          
  Con…                                                                          
  con…                                                                          
  fair          3,169               982             (28,…  )            982     
  val…                                                                          
  adj…                                                                          
  Non…              7                 —             9,292             2,633     
  fees                                                                          
  Loss                                                                          
  (ga…                                                                          
  on                                                                            
  sale                                                                          
  of               83                 —             (59,…  )              —     
  bus…                                                                          
  net                                                                           
  of                                                                            
  tra…                                                                          
  cos…                                                                          
  Str…                                                                          
  col…                                                                          
  and            (121  )            860               116             16,2…     
  lic…                                                                          
  cos…                                                                          
  Net                                                                           
  loss                                                                          
  (ga…                                                                          
  on            12,1…             (1,1…  )          6,795              (785  )  
  inv…                                                                          
  in                                                                            
  equ…                                                                          
  sec…                                                                          
  Acq…                                                                          
  int…                                                                          
  and           46,9…             34,9…             50,0…             62,6…     
  div…                                                                          
  ite…                                                                          
  Oth…           (514  )            (16  )          32,6…             (3,1…  )  
  Inc…                                                                          
  tax                                                                           
  eff…          (38,…  )          (16,…  )          (49,…  )          (50,…  )  
  of                                                                            
  non…                                                                          
  adj…                                                                          
  Adj…                                                                          
  net     $     115,…       $     85,7…       $     315,…       $     305,…     
  inc…                                                                          
  Adj…                                                                          
  net                                                                           
  inc…                                                                          
  as a           29.5  %           22.3  %           27.3  %           26.9  %  
  per…                                                                          
  of                                                                            
  rev…                                                                          
                                                                                
                                                                                
                Three                                Nine                       
                Mont…                               Mont…                       
                Ended                               Ended                       
                Sept…                               Sept…                       
          2026    30,       2025              2026    30,       2025            
 ────────────────────────────────────────────────────────────────────────────── 
  Net                                                                           
  inc…                                                                          
  per     $      0.33       $      0.41       $      3.21       $      2.60     
  sha…                                                                          
  -                                                                             
  dil…                                                                          
  Sto…                                                                          
  and                                                                           
  inc…           0.32              0.36              0.86              0.99     
  plan                                                                          
  com…                                                                          
  Amo…                                                                          
  of                                                                            
  acq…           0.24              0.22              0.75              0.44     
  int…                                                                          
  ass…                                                                          
  Imp…                                                                          
  of             0.45                 —              0.46                 —     
  int…                                                                          
  ass…                                                                          
  Con…                                                                          
  con…                                                                          
  fair           0.05              0.01             (0.43  )           0.01     
  val…                                                                          
  adj…                                                                          
  Non…           0.00                 —              0.14              0.04     
  fees                                                                          
  Loss                                                                          
  (ga…                                                                          
  on                                                                            
  sale                                                                          
  of             0.00                 —             (0.89  )              —     
  bus…                                                                          
  net                                                                           
  of                                                                            
  tra…                                                                          
  cos…                                                                          
  Str…                                                                          
  col…                                                                          
  and           (0.00  )           0.01              0.00              0.24     
  lic…                                                                          
  cos…                                                                          
  Net                                                                           
  loss                                                                          
  (ga…                                                                          
  on             0.18             (0.02  )           0.10             (0.01  )  
  inv…                                                                          
  in                                                                            
  equ…                                                                          
  sec…                                                                          
  Acq…                                                                          
  int…                                                                          
  and            0.69              0.52              0.75              0.91     
  div…                                                                          
  ite…                                                                          
  Oth…          (0.01  )          (0.00  )           0.49             (0.04  )  
  Inc…                                                                          
  tax                                                                           
  eff…          (0.56  )          (0.25  )          (0.74  )          (0.74  )  
  of                                                                            
  non…                                                                          
  adj…                                                                          
  Adj…                                                                          
  net                                                                           
  inc…                                                                          
  per     $      1.68       $      1.27       $      4.70       $      4.43     
  sha…                                                                          
  -                                                                             
  dil…                                                                          
  Wei…                                                                          
  com…                                                                          
  sha…          68,4…             67,6…             67,1…             69,0…     
  out…                                                                          
  -                                                                             
  dil…                                                                          
                                                                                
(a) Represents the estimated income tax effect of the adjustments between GAAP
net income and adjusted net income (non-GAAP). (b) Amounts may not add due to
rounding.
                                   Page7of 11                                   
Lantheus Holdings, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures
(Continued) (in thousands, except per share and percent data – unaudited)
                                                                                
                Three                                Nine                       
                Mont…                               Mont…                       
                Ended                               Ended                       
                Sept…                               Sept…                       
          2026    30,       2025              2026    30,       2025            
 ────────────────────────────────────────────────────────────────────────────── 
  Ope…    $     32,2…       $     43,6…       $     213,…       $     233,…     
  inc…                                                                          
  Sto…                                                                          
  and                                                                           
  inc…          21,8…             24,5…             57,9…             68,0…     
  plan                                                                          
  com…                                                                          
  Amo…                                                                          
  of                                                                            
  acq…          16,7…             14,6…             50,1…             30,6…     
  int…                                                                          
  ass…                                                                          
  Imp…                                                                          
  of            31,0…                 —             31,0…                 —     
  int…                                                                          
  ass…                                                                          
  Con…                                                                          
  con…                                                                          
  fair          3,169               982             (28,…  )            982     
  val…                                                                          
  adj…                                                                          
  Non…              7                 —             9,292             2,633     
  fees                                                                          
  Str…                                                                          
  col…                                                                          
  and              32               860               269             16,2…     
  lic…                                                                          
  cos…                                                                          
  Acq…                                                                          
  int…                                                                          
  and           46,1…             34,9…             55,4…             62,6…     
  div…                                                                          
  ite…                                                                          
  Oth…          2,011               (16  )          35,1…             1,557     
  Adj…                                                                          
  ope…    $     153,…       $     119,…       $     424,…       $     416,…     
  inc…                                                                          
  Adj…                                                                          
  ope…                                                                          
  inc…                                                                          
  as a           39.3  %           31.1  %           36.7  %           36.7  %  
  per…                                                                          
  of                                                                            
  rev…                                                                          
                                                                                
                                   Page8of 11                                   
Lantheus Holdings, Inc. Reconciliation of Free Cash Flow (in thousands –
unaudited)
                                                                                
                Three                                Nine                       
                Mont…                               Mont…                       
                Ended                               Ended                       
                Sept…                               Sept…                       
          2026    30,       2025              2026    30,       2025            
 ────────────────────────────────────────────────────────────────────────────── 
  Net                                                                           
  cash                                                                          
  pro…    $     101,…       $     105,…       $     319,…       $     299,…     
  by                                                                            
  ope…                                                                          
  act…                                                                          
  Cap…          (2,0…  )          (10,…  )          (7,6…  )          (27,…  )  
  exp…                                                                          
  Free                                                                          
  cash    $     99,9…       $     94,6…       $     311,…       $     272,…     
  flow                                                                          
  Net                                                                           
  cash                                                                          
  (us…                                                                          
  in)     $     (11,…  )    $     (319…  )    $     12,8…       $     (615…  )  
  pro…                                                                          
  by                                                                            
  inv…                                                                          
  act…                                                                          
  Net                                                                           
  cash                                                                          
  used    $      (460  )    $     (99,…  )    $     (7,5…  )    $     (215…  )  
  in                                                                            
  fin…                                                                          
  act…                                                                          
                                                                                
                                   Page9of 11                                   
Lantheus Holdings, Inc. Condensed Consolidated Balance Sheets (in thousands –
unaudited)
                                                                                
  Assets                   September 30,               December 31,             
  Current assets:          2026                        2025                     
 ────────────────────────────────────────────────────────────────────────────── 
  Cash and cash            $                683,610    $               359,121  
  equivalents                                                                   
  Accounts receivable,                      345,684                    358,640  
  net                                                                           
  Inventory, net                             64,212                     64,674  
  Income tax receivable                           —                     15,387  
  Other current assets                       30,204                     21,400  
  Assets held for sale                            —                     80,742  
  Total current assets                    1,123,710                    899,964  
  Investment in equity                       98,427                     42,213  
  securities                                                                    
  Long-term notes                            25,297                          —  
  receivable                                                                    
  Property, plant and                       149,627                    163,686  
  equipment, net                                                                
  Intangibles, net                          641,612                    722,779  
  Goodwill                                  238,626                    239,517  
  Deferred tax assets,                      121,135                    109,196  
  net                                                                           
  Other long-term                            57,699                     50,044  
  assets                                                                        
  Total assets             $              2,456,133    $             2,227,399  
  Liabilities and                                                               
  Stockholders’ Equity                                                          
  Current liabilities:                                                          
  Current portion of                                                            
  long-term debt and       $                    605    $                   738  
  other borrowings                                                              
  Accounts payable                           47,700                     42,906  
  Accrued expenses and                                                          
  other current                             297,662                    267,307  
  liabilities                                                                   
  Liabilities held for                            —                     22,468  
  sale                                                                          
  Total current                             345,967                    333,419  
  liabilities                                                                   
  Asset retirement                              257                        138  
  obligations                                                                   
  Long-term debt and                                                            
  other borrowings, net                     571,136                    568,678  
  of current portion                                                            
  Long-term deferred                         41,136                     54,246  
  tax liabilities                                                               
  Long-term contingent                                                          
  consideration                              51,657                     73,255  
  liabilities, net of                                                           
  current portion                                                               
  Other long-term                            90,268                    107,866  
  liabilities                                                                   
  Total liabilities                       1,100,421                  1,137,602  
  Total stockholders’                     1,355,712                  1,089,797  
  equity                                                                        
  Total liabilities and                                                         
  stockholders’            $              2,456,133    $             2,227,399  
  equity                                                                        
                                                                                
                                  Page10of 11                                   
Contacts:                                                                       
                                                                                
Mark Kinarney                                                                   
                                                                                
Vice President, Investor Relations                                              
                                                                                
978-671-8842                                                                    
                                                                                
[email protected]                                                                 
                                                                                
Melissa Downs                                                                   
                                                                                
Executive Director, External Communications                                     
                                                                                
646-975-2533                                                                    
                                                                                
[email protected]                                                              
                                  Page11of 11                                   

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/LNTH/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.